SG10202111905PA - Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof - Google Patents

Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Info

Publication number
SG10202111905PA
SG10202111905PA SG10202111905PA SG10202111905PA SG10202111905PA SG 10202111905P A SG10202111905P A SG 10202111905PA SG 10202111905P A SG10202111905P A SG 10202111905PA SG 10202111905P A SG10202111905P A SG 10202111905PA SG 10202111905P A SG10202111905P A SG 10202111905PA
Authority
SG
Singapore
Prior art keywords
antibodies
methods
combination
programmed death
death receptor
Prior art date
Application number
SG10202111905PA
Inventor
Arnab De
Chakravarthy Nachu Narasimhan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64016405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202111905P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG10202111905PA publication Critical patent/SG10202111905PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG10202111905PA 2017-05-02 2018-05-01 Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof SG10202111905PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762500278P 2017-05-02 2017-05-02

Publications (1)

Publication Number Publication Date
SG10202111905PA true SG10202111905PA (en) 2021-12-30

Family

ID=64016405

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909941Q SG11201909941QA (en) 2017-05-02 2018-05-01 Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG10202111905PA SG10202111905PA (en) 2017-05-02 2018-05-01 Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201909941Q SG11201909941QA (en) 2017-05-02 2018-05-01 Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Country Status (15)

Country Link
US (2) US20200354453A1 (en)
EP (1) EP3618855A4 (en)
JP (2) JP7402693B2 (en)
KR (1) KR20190142394A (en)
CN (1) CN110603052A (en)
AU (1) AU2018261080A1 (en)
BR (1) BR112019022698A2 (en)
CA (1) CA3061050A1 (en)
CL (1) CL2019003145A1 (en)
CO (1) CO2019012356A2 (en)
IL (1) IL270175B2 (en)
MA (1) MA50661A (en)
MX (1) MX2019013033A (en)
SG (2) SG11201909941QA (en)
WO (1) WO2018204405A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
CN115925931A (en) * 2015-08-14 2023-04-07 默沙东公司 anti-TIGIT antibody
TWI805582B (en) 2017-05-01 2023-06-21 美商艾吉納斯公司 Anti-tigit antibodies and methods of use thereof
BR112019022873A8 (en) 2017-05-02 2023-04-11 Merck Sharp & Dohme FORMULATION, AND, INJECTION VESSEL OR DEVICE.
CN112105343B (en) * 2018-03-07 2024-07-30 辉瑞公司 Anti-PD-1 antibody compositions
EP3876978A4 (en) * 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2020120730A1 (en) * 2018-12-14 2020-06-18 Morphosys Ag Antibody formulations
US20220162310A1 (en) * 2019-06-13 2022-05-26 Green Cross Corporation Antibody to tigit and use thereof
US20220273796A1 (en) * 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
CN112741804A (en) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 Stable formulations containing anti-PD-L1 antibodies
CA3168600A1 (en) * 2020-01-21 2021-07-29 Innovent Biologics (Suzhou) Co., Ltd. Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof
IL294375A (en) * 2020-01-24 2022-08-01 Regeneron Pharma Stable antibody formulation
CN111995681B (en) * 2020-05-09 2022-03-08 华博生物医药技术（上海）有限公司 anti-TIGIT antibody, preparation method and application thereof
TW202200616A (en) 2020-06-18 2022-01-01 美商建南德克公司 Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CN111718415B (en) * 2020-07-03 2021-02-23 上海洛启生物医药技术有限公司 anti-TIGIT nano antibody and application thereof
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
AR124712A1 (en) 2021-01-29 2023-04-26 Merck Sharp & Dohme COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS FOR OBTAINING THE COMPOSITIONS THEREOF
AR125753A1 (en) 2021-05-04 2023-08-09 Agenus Inc ANTI-TIGIT ANTIBODIES, ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THESE
KR20240038043A (en) * 2021-07-23 2024-03-22 아케소 바이오파마, 인크. Pharmaceutical compositions and uses
JP2024527049A (en) 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド Methods and Compositions for Treating Cancer
TW202321308A (en) 2021-09-30 2023-06-01 美商建南德克公司 Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN114106182B (en) * 2022-01-26 2022-05-17 中山康方生物医药有限公司 Antibodies against TIGIT and uses thereof
WO2023198116A1 (en) * 2022-04-14 2023-10-19 Beigene Switzerland Gmbh Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024030458A2 (en) * 2022-08-04 2024-02-08 Merck Sharp & Dohme Llc Methods for determining one or more critical quality attributes of co-formulated antibodies
WO2024140651A1 (en) * 2022-12-27 2024-07-04 上海复宏汉霖生物技术股份有限公司 Pharmaceutical preparation comprising anti-tigit antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
JP2012533548A (en) * 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド Method for inhibiting yellowing and peroxide formation in compositions
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
MX341076B (en) * 2011-03-31 2016-08-04 Merck Sharp & Dohme Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments.
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9873740B2 (en) * 2013-07-16 2018-01-23 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
CN113583131B (en) * 2014-08-19 2024-09-03 默沙东有限责任公司 Anti-TIGIT antibodies
SG11201705063VA (en) * 2014-12-23 2017-07-28 Bristol Myers Squibb Co Antibodies to tigit
JP2018531914A (en) 2015-09-14 2018-11-01 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Compositions and methods for treating cancer via CD155 / TIGIT pathway and antagonists of TGF-β
WO2017112621A1 (en) * 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies

Also Published As

Publication number Publication date
KR20190142394A (en) 2019-12-26
EP3618855A4 (en) 2021-02-17
MX2019013033A (en) 2020-02-05
US20240182573A1 (en) 2024-06-06
JP7402693B2 (en) 2023-12-21
EP3618855A1 (en) 2020-03-11
CO2019012356A2 (en) 2020-01-17
WO2018204405A1 (en) 2018-11-08
MA50661A (en) 2020-08-05
IL270175B2 (en) 2023-09-01
AU2018261080A1 (en) 2019-11-07
CN110603052A (en) 2019-12-20
IL270175A (en) 2019-12-31
SG11201909941QA (en) 2019-11-28
RU2019138519A (en) 2021-06-02
RU2019138519A3 (en) 2021-08-30
CA3061050A1 (en) 2018-11-08
JP2024016177A (en) 2024-02-06
CL2019003145A1 (en) 2020-07-10
US20200354453A1 (en) 2020-11-12
IL270175B1 (en) 2023-05-01
BR112019022698A2 (en) 2020-05-19
JP2020518600A (en) 2020-06-25

Similar Documents

Publication Publication Date Title
IL270175B1 (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3618866A4 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3618808A4 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3876978A4 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
HUE062927T2 (en) Anti-tigit antibodies and methods of use thereof
IL267902A (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
IL270235B1 (en) Anti-trem2 antibodies and methods of use thereof
HUE050279T2 (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1258007A1 (en) Human programmed cell death 1 receptor antibody, method of preparing same, and use thereof
IL268704B (en) Formulations of human anti-rankl antibodies, and methods of using the same
IL269077A (en) Anti-gitr antibodies and methods of use thereof
IL285928A (en) Fulvestrant formulations and methods of their use
EP3731867A4 (en) Anti-lrp5/6 antibodies and methods of use
EP3630046A4 (en) Anti-doublecortin-like kinase 1 antibodies and methods of use
GB201621818D0 (en) Cosmetic composition and use thereof
IL275739A (en) Compositions for cryopreservation and methods of use thereof
ZA201907063B (en) Insecticidal proteins and methods for their use
IL274221A (en) Anti-apoc3 antibodies and methods of use thereof
EP3433035A4 (en) Compositions and methods of use thereof in sandcasting
IL264403A (en) Vortioxetine analogue and use and preparation thereof
EP3694488A4 (en) Hydroxychloroquine sulfate formulations and methods for preparation and use thereof
IL274433A (en) Fulvestrant formulations and methods of their use
SG11202105525YA (en) Monomethyl fumarate-carrier conjugates and methods of their use
PL3426017T3 (en) Hydroponic tiliacora triandra and use thereof
EP3724351A4 (en) Pheromone compositions for stimulating early onset of estrus and reducing labor needs in breeding peri-pubertal suids and methods of use